Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain
Modeling Kappa Opioid Analgesic Mechanisms in Chronic Orofacial Pain Disorders
Sponsor: University of California, San Francisco
Terminated
Unable to recruit a sufficient number of subjects.
Other terminated trials from University of California, San Francisco
- Hypertension · Phase PHASE2 · Jan 2026
- Menstrual Irregularity · Phase PHASE4 · Sep 2025
- Diabetes Mellitus, Type 2 · Phase NA · Feb 2025
- Asthma · Phase PHASE4 · Feb 2025
- Stone, Kidney · Phase NA · Dec 2024
See all terminations from University of California, San Francisco
Listed as NCT00716807, this NA trial focuses on Burning Mouth Syndrome and Temporomandibular Joint Dysfunction Syndrome and remains terminated or withdrawn. Sponsored by University of California, San Francisco, it has been updated 9 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
-
Dec 2021 — Dec 2022 [monthly]
Terminated NA
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
-
Feb 2017 — Jun 2018 [monthly]
Terminated NA
-
Jan 2017 — Feb 2017 [monthly]
Terminated NA
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .